Salmeterol use and risk of hospitalization among emergency department patients with acute asthma

Annals of Allergy, Asthma and Immunology

Volumn 104, Issue 6, 2010, Pages 478-484

  Liao, Michael M ^a,b   Ginde, Adit A ^b   Clark, Sunday ^c   Camargo Jr , Carlos A ^d  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG USE; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; CHILD; COHORT STUDIES; EMERGENCIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77953163429     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.04.014     Document Type: Article

References (33)

1. Moorman J.E., Rudd R.A., Johnson C.A., et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 56 (2007) 1-54
2. Centers for Disease Control and Prevention. National Center for Health Statistics, National Health Interview Survey (NHIS) Data; 2006 Lifetime and Current Asthma. http://www.cdc.gov/asthma/nhis/06/data.htm Accessed July 25, 2009
3. Weiss K.B., and Sullivan S.D. The health economics of asthma and rhinitis, I: assessing the economic impact. J Allergy Clin Immunol 107 (2001) 3-8
4. Expert Panel Report 3 (EPR-3). guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120 5 suppl (2007) S94-S138
5. Ginde A.A., Espinola J.A., and Camargo Jr. C.A. Improved overall trends but persistent racial disparities in emergency department visits for acute asthma, 1993-2005. J Allergy Clin Immunol 122 (2008) 313-318
6. Drazen J.M., and O'Byrne P.M. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 360 (2009) 1671-1672
7. Kramer J.M. Balancing the benefits and risks of inhaled long-acting beta-agonists: the influence of values. N Engl J Med 360 (2009) 1592-1595
8. Sears M.R. Safety of long-acting beta-agonists: are new data really required?. Chest 136 (2009) 604-607
9. Rodrigo G.J., Moral V.P., Marcos L.G., and Castro-Rodriguez J.A. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review. Pulm Pharmacol Ther 22 (2009) 9-19
10. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
11. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
12. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical Briefing Package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee (December 10-11, 2008), Food and Drug Administration, Rockville, MD. http://www.fda.gov/ohrms/dockets/ac/cder08.html#PulmonaryAllergy Accessed July 10, 2009
13. Beasley R., Martinez F.D., Hackshaw A., Rabe K.F., Sterk P.J., and Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 33 (2009) 3-5
14. Grove A., and Lipworth B.J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346 (1995) 201-206
15. Lipworth B.J., and Jackson C.M. Salmeterol and tolerance. Chest 117 (2000) 609-611
16. Dougherty R.H., and Fahy J.V. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 39 (2009) 193-202
17. Griswold S.K., Nordstrom C.R., Clark S., Gaeta T.J., Price M.L., and Camargo Jr. C.A. Asthma exacerbations in North American adults: who are the "frequent fliers" in the emergency department?. Chest 127 (2005) 1579-1586
18. Moore W.C., Bleecker E.R., Curran-Everett D., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119 (2007) 405-413
19. Weber E.J., Silverman R.A., Callaham M.L., et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 113 (2002) 371-378
20. Tsai C.L., Sullivan A.F., Gordon J.A., et al. Quality of care for acute asthma in 63 US emergency departments. J Allergy Clin Immunol 123 (2009) 354-361
21. Emergency Medicine Network (2009), EMNet Coordinating Center, Boston, MA. http://www.emnet-usa.org/ Accessed July 10, 2009
22. The Sourcebook of Zip Code Demographics. 12th ed. (1997), CACI Marketing Systems, Fairfax, VA
23. Federal Census Data (1996), Statistics Canada, Ottawa, Canada
24. Hankinson J.L., Odencrantz J.R., and Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999) 179-187
25. Katz M.H. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 138 (2003) 644-650
26. Korosec M., Novak R.D., Myers E., Skowronski M., and McFadden Jr. E.R. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 107 (1999) 209-213
27. Cates C.J., and Cates M.J. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 3 (2008) CD006363
28. Jaeschke R., O'Byrne P.M., Mejza F., et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 178 (2008) 1009-1016
29. Bateman E., Nelson H., Bousquet J., et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149 (2008) 33-42
30. Ni C.M., Greenstone I.R., and Ducharme F.M. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev 2 (2005) CD005307
31. Ni Chroinin.M., Greenstone I.R., Danish A., et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 4 (2005) CD005535
32. Greenstone I.R., Ni C.M., Masse V., et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 4 (2005) CD005535
33. Clark S., Costantino T., Rudnitsky G., and Camargo Jr. C.A. Observational study of intravenous versus oral corticosteroids for acute asthma: an example of confounding by severity. Acad Emerg Med 12 (2005) 439-445